New hope for Hard-to-Treat cancers: enhertu studied in 20+ tumor types

NCT ID NCT07124000

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 5 times

Summary

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and for how long. The study covers many cancer types, such as bladder, cervical, ovarian, and pancreatic cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Trastuzumab deruxtecan (Enhertu)
What this could lead to
If successful, this could show that T-DXd is an effective treatment option for many types of HER2-positive cancers that have stopped responding to other therapies.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. The drug may not work for all tumor types, and side effects like lung inflammation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA (NOS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Birmingham, Alabama, 35243, United States

  • Research Site

    RECRUITING

    Bullhead City, Arizona, 86442, United States

  • Research Site

    RECRUITING

    Casa Grande, Arizona, 85122, United States

  • Research Site

    RECRUITING

    San Diego, California, 92123, United States

  • Research Site

    RECRUITING

    Boulder, Colorado, 80309, United States

  • Research Site

    RECRUITING

    Coral Springs, Florida, 33065, United States

  • Research Site

    RECRUITING

    St. Petersburg, Florida, 33714, United States

  • Research Site

    RECRUITING

    West Palm Beach, Florida, 33401, United States

  • Research Site

    RECRUITING

    Decatur, Illinois, 62526, United States

  • Research Site

    RECRUITING

    Topeka, Kansas, 66604, United States

  • Research Site

    RECRUITING

    Farmington, New Mexico, 87401, United States

  • Research Site

    RECRUITING

    Durham, North Carolina, 27708, United States

  • Research Site

    RECRUITING

    Wilson, North Carolina, 27893, United States

  • Research Site

    RECRUITING

    Canton, Ohio, 44718, United States

  • Research Site

    RECRUITING

    Maumee, Ohio, 43537, United States

  • Research Site

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Research Site

    RECRUITING

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.